Psyence Biomedical Ltd.
corporate_fare Company Profile
Psyence Biomedical Ltd. (NASDAQ:PBM) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for PBM at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-19, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for PBM spans 6-K, SCHEDULE 13D/A, 20-F, SCHEDULE 13D.
Recent high-impact activity:
- Psyence BioMed Posts $1.94M H1 Loss, $21.1M Cash; PsyLabs Stake Hits 43.4%
- Psyence Completes US$2.6M PsyLabs Backstop as Ibogaine Milestones Met
- PsyLabs Closes Swap, Holds 49.75% of Psyence Biomedical at US$6.00/Share
- Psyence BioMed Adds DEA-Registered Benuvia for U.S. Ibogaine Manufacturing
- Psyence BioMed's Texas Subsidiary Secures Exclusive U.S. Ibogaine License from Related-Party PsyLabs
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 19,062 shares in PBM as of the October 30, 2026 settlement, a 6.1% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 27.3% of PBM volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for PBM, detected from its recent SEC filings · based on capital-structure filings through 2026-06-22.
Significant Net Loss Reported · Massive Dilution from Equity Line of Credit
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
PBM files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.